NCT07340814尚未招募不适用
A Long-term Follow-up Study of Patients Who Received MB-105
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 40
- 主要终点
- Assess long term safety of MB-105 in patients who received MB-105
研究概览
简要总结
This study is to fulfil the regulatory requirement for 15-year follow-up for patients treated with MB-105 in any study
详细描述
This study is for long term follow up of efficacy and safety for any patient treated with MB-105 who has consented to joining the LTFU study. There are no exclusion criteria.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Received MB-105 Signed informed consent Agree to transfer of samples from previous study Able to comply with study requirements
排除标准
- 未提供
研究组 & 干预措施
Open Observation
All patients who previously received MB-105 on another study
干预措施: MB-105 (Biological)
结局指标
主要结局
Assess long term safety of MB-105 in patients who received MB-105
时间窗: 15 Years
SAEs
次要结局
- Assess long term efficacy of MB-105 in patients who received MB-105(15 Years)
研究者
相似试验
招募中
2 期
Phase II multicentric study: efficacy evaluation of neo-adjuvant treatment associated with maintenance therapy by anti-PD1 immunotherapy on disease-free-survival (DFS) in patients with resectable mucosal melanoma2024-513027-16-00Institut Gustave Roussy60
尚未招募
1 期
A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid TumorNCT07327294Evopoint Biosciences Inc.150
招募中
2 期
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy (MecMeth/ NOA-24)Glioblastoma2024-511264-89-00Rheinische Friedrich-Wilhelms-Universitaet Bonn72
尚未招募
3 期
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese CohortPulmonary TuberculosisTuberculosisDrug-resistant TuberculosisNCT07268664Beijing Chest Hospital120
终止
不适用
A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous UrticariaNCT07316114Sanofi1